Profiel
Joanne Palmer is currently the Head of Clinical Operations at Convergence Pharmaceuticals Ltd.
and the Chief Development Officer at Eliem Therapeutics, Inc. She previously worked at GSK Plc as a Principal.
Actieve functies van Joanne Palmer
| Bedrijven | Functie | Begin |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06-10-2010 |
Eerdere bekende functies van Joanne Palmer
| Bedrijven | Functie | Einde |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GSK PLC | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
